PsyBio Therapeutics announced that it has filed six additional provisional manufacturing patent applications to expand its intellectual property portfolio.
The Oxford, Ohio-based biotech company said that the new manufacturing patents cover a broad range of approaches to its biologic methodology as it pertains to the current landscape of biotechnology.
"These patent filings are critical components of PsyBio's corporate development strategy. Continuing to add intellectual property protection provides us with certainty when developing technology for the exclusive use of our team as we continue to develop proprietary bacterial strains," said Michael Spigarelli, PsyBio's chief medical officer in a release.
READ: PsyBio says it has obtained receipts for final base shelf prospectus; aims to streamline access to company investment
He added: "These additional patent filings are key as PsyBio moves towards the initiation of appropriately approved safety and efficacy clinical trials for our selected compounds within the production and manufacturing arena, for the company as well as for our investors."
PsyBio said that it remains interested in developing the intellectual property landscape within the psycho-targeted development drug arena.
"Adding these new patent applications to our existing intellectual property portfolio demonstrates PsyBio's commitment to being a leader in developing psycho-targeted therapeutic candidates," said Evan Levine, PsyBio's CEO.
Levine noted that the company’s approach is to treat intellectual property as a critical part of effectively designing and developing therapeutics to treating specific clinical conditions.
“Submitting those to the appropriate agencies for approval and regulatory authorization to uphold our commitment to help improve mental and neurological health," he said.
PsyBio Therapeutics, an intellectual property-driven biotechnology company, is developing new psycho-targeted therapeutics to potentially improve mental and neurological health. Research and development are currently ongoing for naturally occurring psychoactive tryptamines originally discovered in different varieties of hallucinogenic mushrooms, other tryptamines and phenethylamines, and combinations.
Contact Ritika at ritika@proactiveinvestors.com